title: Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid.
abstract: OBJECTIVE
  To ascertain the molecule mechanism of nuclear factor-kappaB (NF-kappaB) inhibitor curcumin preventive and therapeutic effects in rats' colitis induced by trinitrobenzene sulfonic acid (TNBS).
  
  
  METHODS
  Sixty rats with TNBS-induced colitis were treated with 2.0% curcumin in the diet. Thirty positive control rats were treated with 0.5% sulfasalazine (SASP). Thirty negative control rats and thirty model rats were treated with general diet. Changes of body weight together with histological scores were evaluated. Survival rates were also evaluated. Cell nuclear NF-kappaB activity in colonic mucosa was evaluated by using electrophoretic mobility shift assay. Cytoplasmic IkappaB protein in colonic mucosa was detected by using Western Blot analysis. Cytokine messenger expression in colonic tissue was assessed by using semiquantitative reverse-transcription polymerase chain reaction.
  
  
  RESULTS
  Treatment with curcumin could prevent and treat both wasting and histopathologic signs of rats with TNBS-induced intestinal inflammation. In accordance with these findings, NF-kappaB activation in colonic mucosa was suppressed in the curcumin-treated groups. Degradations of cytoplasmic IkappaB protein in colonic mucosa were blocked by curcumin treatment. Proinflammatory cytokine messenger RNA expression in colonic mucosa was also suppressed.
  
  
  CONCLUSIONS
  This study shows that NF-kappaB inhibitor curcumin could prevent and improve experimental colitis in murine model with inflammatory bowel disease (IBD). The findings suggest that NF-kappaB inhibitor curcumin could be a potential target for the patients with IBD.
authors.affiliation: Chinese PLA Institute of Digestive Disease, Nanfang Hospital, First Military Medical University, Guangzhou 510515, Guangdong Province, China.
authors.forename: Yan-Ting
authors.initials: YT
authors.lastname: Jian
authors.forename: Guo-Feng
authors.initials: GF
authors.lastname: Mai
authors.forename: Ji-De
authors.initials: JD
authors.lastname: Wang
authors.forename: Ya-Li
authors.initials: YL
authors.lastname: Zhang
authors.forename: Rong-Cheng
authors.initials: RC
authors.lastname: Luo
authors.forename: Yong-Xin
authors.initials: YX
authors.lastname: Fang
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D001835:Body Weight / Q000187:drug effects; D003092:Colitis / Q000139:chemically induced* / Q000188:drug therapy* / Q000401:mortality; D003474:Curcumin / Q000494:pharmacology*; D016207:Cytokines / Q000235:genetics; D003593:Cytoplasm / Q000378:metabolism; D015870:Gene Expression / Q000187:drug effects / Q000276:immunology; D020672:I-kappa B Proteins / Q000378:metabolism; D007413:Intestinal Mucosa / Q000276:immunology / Q000473:pathology; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D051381:Rats; D017208:Rats, Wistar; D015996:Survival Rate; D014302:Trinitrobenzenesulfonic Acid
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D020672:I-kappa B Proteins; D016328:NF-kappa B; D014302:Trinitrobenzenesulfonic Acid; D003474:Curcumin